Curanex Stock Sinks Toward 31 Cents as Nasdaq Clock Ticks
Curanex Pharmaceuticals shares fell 6.5% to $0.3104 on Friday, with volume near 100,000, leaving the company below Nasdaq’s $1 minimum bid and facing a Nov. 2 compliance deadline. Its lead drug, Phyto-N, remains preclinical, with an FDA investigational new drug application planned for the fourth quarter.